

Skärmbild film Vanflyta:



VANFLYTA + STANDARD CHEMOTHERAPY DEMONSTRATED A **22% REDUCTION**
IN THE RISK OF DEATH VS PLACEBO + STANDARD CHEMOTHERAPY^{2*}

VANFLYTA REDUCED THE RISK OF RELAPSE OR DEATH BY 39%^{2†}

PATIENTS ACHIEVED AN ADDITIONAL **26.2-MONTH DURATION**
OF COMPLETE REMISSION WITH VANFLYTA^{2‡}

*22% reduction in risk of death calculated from the HR=0.78 (95% CI: 0.63-0.98); p=0.032. †Hazard ratio is based on a stratified Cox proportional hazard model by the stratified factors used in randomisation.
‡The p-value was calculated using a two-sided stratified log-rank test.
††39% reduced risk of relapse or death calculated from the HR=0.61 (95% CI: 0.44-0.85).
‡‡26.2 months calculated as the difference in duration of complete remission between VANFLYTA and placebo (38.6 months, 95% CI: 21.9-45.4 vs 12.4 months, 95% CI: 8.9-22.7; HR=0.62, 0.45-0.86).¹

